Primary Myelofibrosis Market Outlook 2025: Opportunities and Emerging Challenges

 Save 20% on All Global Market Reports With Code ONLINE20 — Gain Insights Into Tariffs, Inflation, and Industry Trends

 

 What Is the Projected Growth Rate of the Primary Myelofibrosis Market Through 2029?
 The primary myelofibrosis market size has grown strongly in recent years. It will grow from $0.79 billion in 2024 to $0.84 billion in 2025 at a compound annual growth rate (CAGR) of 6.4%. The growth in the historic period can be attributed to increasing disease awareness among clinicians, rising use of jak inhibitors, growing diagnostic capabilities and genetic testing, increasing patient access to hematology specialists and rising clinical trial activity.
 
 The primary myelofibrosis market size is expected to see strong growth in the next few years. It will grow to $1.07 billion in 2029 at a compound annual growth rate (CAGR) of 6.2%. The growth in the forecast period can be attributed to growing pipeline of novel therapies, increasing demand for disease-modifying treatments, rising prevalence in aging populations, growing emphasis on combination therapies and increasing investment from pharma and biotech firms. Major trends in the forecast period include advancements in targeted drug development, integration of next-generation sequencing (ngs) in diagnostics, technology-driven monitoring solutions, developments in combination therapy protocols and advancements in bone marrow fibrosis imaging techniques.
 
 Claim your free report sample now:
 https://www.thebusinessresearchcompany.com/sample.aspx?id=24669&type=smp
 
 Which Major Growth Factors Are Shaping the Primary Myelofibrosis Market?
 The increasing prevalence of myelofibrosis is expected to propel the growth of the primary myelofibrosis market going forward. Myelofibrosis refers to a rare type of bone marrow cancer that disrupts the body’s normal production of blood cells, leading to extensive scarring in the bone marrow and resulting in severe anemia, weakness, fatigue, and an enlarged spleen. The increasing prevalence of myelofibrosis is primarily due to the aging population, as the condition most commonly affects individuals over the age of 60, and longer life expectancy is contributing to a higher number of diagnosed cases. The rising prevalence of myelofibrosis improves the management of primary myelofibrosis by driving research, enhancing early diagnosis, increasing treatment options, and promoting better clinical guidelines and specialized care. For instance, in November 2024, according to the report published by the National Institute for Health and Care Excellence, a UK-based independent executive non-departmental public body, myelofibrosis has a prevalence of 3.2 per 100,000 people in the UK and an incidence rate of 0.6 per 100,000. Therefore, the increasing prevalence of myelofibrosis is driving the growth of the primary myelofibrosis market.
 
 Which Segment Offers the Highest Growth Opportunities in the Primary Myelofibrosis Market?
 The primary myelofibrosis market covered in this report is segmented — 
 
 1) By Type: Spinocerebellar Primary Myelofibrosiss, Primary Myelofibrosis-Telangiectasia, Episodic Primary Myelofibrosis, Other Types
 2) By Services: Treatment, Diagnosis
 3) By Dosage Forms: Solid, Liquids, Other Dosage Forms
 4) By Age: Adult, Child, Geriatric
 5) By End User: Hospitals, Clinics, Other End Users
 
 Subsegments:
 1) By Spinocerebellar Primary Myelofibrosis: Spinocerebellar Ataxia With Myelofibrosis, Hereditary Spinocerebellar Degeneration With Bone Marrow Fibrosis, Neurodegenerative Spinocerebellar Syndromes With Fibrotic Manifestations
 2) By Primary Myelofibrosis-Telangiectasia: Cutaneous Telangiectasia With Myelofibrosis, Hereditary Hemorrhagic Telangiectasia With Marrow Fibrosis, Ocular Telangiectasia-Associated Myelofibrosis
 3) By Episodic Primary Myelofibrosis: Intermittent Marrow Fibrosis Episodes, Periodic Cytopenia With Fibrosis Flare, Cyclical Myelofibrosis In Autoimmune Disorders
 4) By Other Types: Familial Primary Myelofibrosis, Idiopathic Myelofibrosis, Therapy-Related Primary Myelofibrosis, Juvenile Primary Myelofibrosis
 
 Which Emerging Trends Are Driving the Primary Myelofibrosis Market?
 Major companies operating in the primary myelofibrosis market are focusing on developing innovative products such as Janus kinase 2 inhibiting tablets to improve symptom control and slow disease progression. Janus kinase 2 (JAK2) inhibiting tablets are oral medications that block the activity of the JAK2 enzyme, which is involved in the abnormal signaling pathways that cause excessive blood cell production in primary myelofibrosis. These tablets help reduce spleen size, alleviate fatigue and bone pain symptoms, and slow disease progression. For instance, in March 2025, GlaxoSmithKline Korea (GSK Korea) Ltd., a Korea-based pharmaceutical and biotechnology company, launched Omjjara (momelotinib), a new treatment for myelofibrosis. It is approved by South Korea’s Ministry of Food and Drug Safety and intended for adult patients with intermediate- or high-risk primary or secondary myelofibrosis who also experience moderate to severe anemia. Omjjara is an oral medication that inhibits Janus kinases (JAK1 and JAK2) and activin A receptor type 1 (ACVR1), effectively addressing symptoms such as anemia, enlarged spleen, and fatigue. Its approval is supported by clinical trial data demonstrating significant improvements in anemia, spleen size, and overall symptoms compared to existing treatments.
 
 Who Are the Key Players Driving the Primary Myelofibrosis Market?
 Major companies operating in the primary myelofibrosis market are Merck & Co. Inc., AbbVie Inc., Bristol-Myers Squibb Company, Sumitomo Pharma Oncology Inc., Incyte Corporation, Nippon Shinyaku Co. Ltd., MorphoSys AG, Keros Therapeutics Inc., Geron Corporation, Lynk Pharmaceuticals Co. Ltd., Pharmaxis Ltd, Kartos Therapeutics Inc., Disc Medicine Inc., Galecto Inc., Cellenkos Inc., Chia Tai Tianqing Pharmaceutical Group Co. Ltd., Taiga Biotechnologies Inc., Suzhou Zelgen Biopharmaceuticals Co. Ltd., Telios Pharma Inc., Samus Therapeutics Inc., Jacobio Pharmaceuticals Co. Ltd. 
 
 Get the full primary myelofibrosis market report here:
 https://www.thebusinessresearchcompany.com/report/primary-myelofibrosis-global-market-report
 
 What Are the Regional Insights for the Primary Myelofibrosis Market Forecast?
 North America was the largest region in the primary myelofibrosis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the primary myelofibrosis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
 
 Contact Us:
 
 The Business Research Company 
 
 https://thebusinessresearchcompany.com/ 
 
 Americas +1 310–496–7795
 Asia +44 7882 955267 & +91 8897263534
 Europe +44 7882 955267 
 
 Email: info@tbrc.info 
 
 
 Follow Us On:
 
 LinkedIn: https://in.linkedin.com/company/the-business-research-company